About BBT

BB_logo.jpg

Every 15 seconds, someone in the US suffers a traumatic brain injury

 

Beyond Barriers Therapeutics, Inc. is developing a novel product to treat inflammation and cell death following traumatic brain injury (TBI). Building upon promising research from the National Institutes of Health, our product uses a unique mechanism to deliver therapeutic drugs to the brain.

Every 15 seconds, an American suffers a traumatic brain injury (TBI), hospitalizing 230,000 people annually at a cost of more than $50 billion. Because of a lack of specific therapies for TBI, people are mainly treated with a "wait and see" approach. Our veterans, children, and elderly deserve more.

We are developing a treatment that could be administered intranasally immediately after impact to the head, which would help prevent secondary injury to the brain. In the hours and days following initial injury, toxic molecules and dangerous inflammation can occur in the brain, contributing to debilitating long-term disabilities for patients. Our treatment aims to decrease these harmful effects by providing active therapy.

 

In addition to significantly improving standard of care for patients suffering from TBI, our proprietary technology will lay the foundation for use of a novel, more effective delivery mechanism of small molecules to the brain. After successful testing, this technology could be used to treat a number of other neurological conditions (such as Depression or Alzheimer’s Disease)--generating value throughout the healthcare system.

Meet the Team

RyanKole_Headshot.jpg

Ryan Kole, MBA
CEO

Venture Capitalist

 

Director of the Midwest Venture Capital Consortium

 

University of Illinois, BA

University of Chicago, MBA

  • Grey LinkedIn Icon
Screen Shot 2020-08-11 at 11.29.11 AM.pn

John Marshall, PhD
Chief Scientific Officer

Neuro-electrophysiologist

Columbia University, BA

Northwestern University, PhD neuroscience

  • Grey LinkedIn Icon
Screen Shot 2020-08-11 at 11.25.44 AM.pn

Tom De Gregoris, JD, MBA
COO, JD/MBA

Attorney and M&A/Private Equity Advisor

University of Notre Dame, BBA

Northwestern University, JD/MBA

  • Grey LinkedIn Icon
unnamed.png

Jeffrey D. Lewine, PhD
Director of Research

Professor of Translational Neuroscience at the MIND Research Network,

 

Director of Neuroscience for Lovelace Scientific Resources,

 

University of Rochester, BA, MS and PhD neuroscience

  • Grey LinkedIn Icon
_a_MG_9455 2 2.jpg

Brian Reinhardt, MS
Project Manager

US Army Veteran

 

Former Director, TMTI Business Operations and Team Lead at Defense Threat Reduction Agency

University of Oklahoma, BS

Georgetown, MS Chemisty

  • Grey LinkedIn Icon